← Leaderboards
Jeffrey Victor Ravetch
Rockefeller University
$66,226,718
Attributed
$75,865,478
Total exposure
34
Grants
26
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $11.4M · FY2005–25$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$133,997,603 · 37
By mechanism
P01$43,310,291 · 9
U19$39,132,010 · 9
R01$36,368,304 · 10
R35$10,515,749 · 1
R37$3,744,331 · 1
R21$501,000 · 1
Top collaborators
- Michel C Nussenzweig10 shared
- Peter Palese10 shared
- Mikael Karlsson6 shared
- Robert Mccullough Anthony5 shared
- Pamela J Bjorkman5 shared
- Eric J Sundberg1 shared
Most similar at Rockefeller University
Same institution · by research overlap
- Stylianos Bournazos$8,462,360
- Jean-Laurent Casanova$36,806,361
- Edgar D Charles$802,000
- Mikael Karlsson$1,356,393
- Jacques F Banchereau$38,021,266
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesImmunoglobulin GMediatingPathway InteractionsIn VivoResponseEngineeringCellsFc DomainAntigensBaseImmunityImmune ResponseMouse ModelReceptorPolysaccharidesVaccinationIn VitroInflammatoryDendritic CellsMacrophageFc ReceptorGenerationsSignal Transduction
Grant awards (192)
Molecular mechanisms of antibody-mediated immunotherapies$1,017,000
R35 · FY2025 · CA · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$845,133
R01 · FY2025 · AI · contact PI
Engineering IgG-specific endoglycosidases to selectively defeat effector functions$663,219
R01 · FY2025 · AI
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$370,726
R01 · FY2025 · CA · contact PI
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$171,731
R01 · FY2025 · CA · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$966,151
R35 · FY2024 · CA · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$862,508
R01 · FY2024 · AI · contact PI
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases$822,968
R01 · FY2024 · AI
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$515,333
R01 · FY2024 · CA · contact PI
Integrating innate and adaptive pathways in vaccine responses$2,087,423
U19 · FY2023 · AI · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$847,458
R01 · FY2023 · AI · contact PI
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases$822,968
R01 · FY2023 · AI
Fc domain effector activity in dengue disease$586,121
U19 · FY2023 · AI · contact PI
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$531,608
R01 · FY2023 · CA · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$447,450
R35 · FY2023 · CA · contact PI
Administrative Core$211,212
U19 · FY2023 · AI · contact PI
Integrating innate and adaptive pathways in vaccine responses$2,087,498
U19 · FY2022 · AI · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$1,017,000
R35 · FY2022 · CA · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$996,658
R35 · FY2022 · CA · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$847,458
R01 · FY2022 · AI · contact PI
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases$822,968
R01 · FY2022 · AI
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$547,420
R01 · FY2022 · CA · contact PI
Fc domain effector activity in dengue disease$417,500
U19 · FY2022 · AI · contact PI
Administrative Core$417,500
U19 · FY2022 · AI · contact PI
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection$130,823
R01 · FY2022 · AI · contact PI
Integrating innate and adaptive pathways in vaccine responses$2,087,668
U19 · FY2021 · AI · contact PI
Integrating innate and adaptive pathways in vaccine responses$1,500,000
U19 · FY2021 · AI · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$1,017,000
R35 · FY2021 · CA · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2021 · AI · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$847,458
R01 · FY2021 · AI · contact PI
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases$822,968
R01 · FY2021 · AI
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection$784,941
R01 · FY2021 · AI · contact PI
Engaging immunosuppressive myeloid cells in the TME for the treatment of pancreatic cancer$575,967
R01 · FY2021 · CA · contact PI
Fc domain effector activity in dengue disease$550,875
U19 · FY2021 · AI · contact PI
Administrative Core$211,458
U19 · FY2021 · AI · contact PI
Integrating innate and adaptive pathways in vaccine responses$2,087,906
U19 · FY2020 · AI · contact PI
Characterization of the antibody responses elicited upon SARS-CoV-2 infection$1,500,000
U19 · FY2020 · AI · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$1,017,000
R35 · FY2020 · CA · contact PI
Project-002$873,905
U19 · FY2020 · AI · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2020 · AI · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$847,458
R01 · FY2020 · AI · contact PI
Examining IgG4 sialylation as a gain of function post-translation modification in IgG4-related diseases$839,968
R01 · FY2020 · AI
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection$654,116
R01 · FY2020 · AI · contact PI
Project-003$626,095
U19 · FY2020 · AI · contact PI
Fc domain effector activity in dengue disease$550,875
U19 · FY2020 · AI · contact PI
Administrative Core$211,695
U19 · FY2020 · AI · contact PI
Integrating innate and adaptive pathways in vaccine responses$2,088,086
U19 · FY2019 · AI · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$986,490
R35 · FY2019 · CA · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$864,833
R01 · FY2019 · AI · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2019 · AI · contact PI
Fc domain effector activity in dengue disease$566,283
U19 · FY2019 · AI · contact PI
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain$377,544
P01 · FY2019 · CA · contact PI
Administrative Core$211,875
U19 · FY2019 · AI · contact PI
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain$27,240
P01 · FY2019 · CA · contact PI
Integrating innate and adaptive pathways in vaccine responses$2,848,678
U19 · FY2018 · AI · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$1,017,000
R35 · FY2018 · CA · contact PI
Role of IgG Fc Glycan Composition in Vaccination$991,876
U19 · FY2018 · AI · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2018 · AI · contact PI
Mechanisms -of Fc-dependent, broad-spectrum, humoral immunity against influenza$428,343
U19 · FY2018 · AI · contact PI
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain$389,221
P01 · FY2018 · CA · contact PI
Administrative Core$228,213
U19 · FY2018 · AI · contact PI
Transgenic Aminal Core$211,902
U19 · FY2018 · AI · contact PI
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain$28,083
P01 · FY2018 · CA · contact PI
Integrating innate and adaptive pathways in vaccine responses$2,433,403
U19 · FY2017 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$2,100,311
P01 · FY2017 · AI
Molecular mechanisms of antibody-mediated immunotherapies$1,017,000
R35 · FY2017 · CA · contact PI
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoir$847,498
R01 · FY2017 · AI · contact PI
Role of IgG Fc Glycan Composition in Vaccination$623,583
U19 · FY2017 · AI · contact PI
Fc effector function in bNAbs$508,500
P01 · FY2017 · AI · contact PI
Mechanisms -of Fc-dependent, broad-spectrum, humoral immunity against influenza$428,342
U19 · FY2017 · AI · contact PI
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain$389,221
P01 · FY2017 · CA · contact PI
Administrative Core$227,118
U19 · FY2017 · AI · contact PI
Transgenic Aminal Core$211,902
U19 · FY2017 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$4,894,251
P01 · FY2016 · AI
Integrating innate and adaptive pathways in vaccine responses$2,433,401
U19 · FY2016 · AI · contact PI
Fc effector function in bNAbs$1,263,378
P01 · FY2016 · AI · contact PI
Molecular mechanisms of antibody-mediated immunotherapies$1,017,000
R35 · FY2016 · CA · contact PI
Role of IgG Fc Glycan Composition in Vaccination$539,278
U19 · FY2016 · AI · contact PI
Mechanisms -of Fc-dependent, broad-spectrum, humoral immunity against influenza$508,017
U19 · FY2016 · AI · contact PI
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain$315,472
P01 · FY2016 · CA · contact PI
Transgenic Aminal Core$251,317
U19 · FY2016 · AI · contact PI
Administrative Core$168,973
U19 · FY2016 · AI · contact PI
Integrating innate and adaptive pathways in vaccine responses$2,433,403
U19 · FY2015 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$2,100,313
P01 · FY2015 · AI
Role of IgG Fc Glycan Composition in Vaccination$541,153
U19 · FY2015 · AI · contact PI
Fc effector function in bNAbs$462,346
P01 · FY2015 · AI · contact PI
Mechanisms -of Fc-dependent, broad-spectrum, humoral immunity against influenza$428,343
U19 · FY2015 · AI · contact PI
Molecular aspects of antitumor antibodies$343,238
R01 · FY2015 · CA · contact PI
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain$315,472
P01 · FY2015 · CA · contact PI
Transgenic Aminal Core$211,902
U19 · FY2015 · AI · contact PI
Administrative Core$174,058
U19 · FY2015 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$2,636,665
P01 · FY2014 · AI
Integrating innate and adaptive pathways in vaccine responses$2,435,437
U19 · FY2014 · AI · contact PI
Fc effector function in bNAbs$947,985
P01 · FY2014 · AI · contact PI
Role of IgG Fc Glycan Composition in Vaccination$553,685
U19 · FY2014 · AI · contact PI
Mechanisms -of Fc-dependent, broad-spectrum, humoral immunity against influenza$517,221
U19 · FY2014 · AI · contact PI
Molecular aspects of antitumor antibodies$343,238
R01 · FY2014 · CA · contact PI
Transgenic Aminal Core$255,870
U19 · FY2014 · AI · contact PI
Administrative Core$172,617
U19 · FY2014 · AI · contact PI
Development Structure and Function of Broadly Neutralizing anti-HIV Antibodies$2,123,313
P01 · FY2013 · AI
Fc effector function in bNAbs$585,723
P01 · FY2013 · AI · contact PI
Study of FcR Genes: Macrophages and Lymphocytes$418,165
R56 · FY2013 · AI · contact PI
Optimizing vaccine efficacy through Fc receptors$397,272
P01 · FY2013 · AI · contact PI
Molecular Aspects of Antitumor Antibodies$304,747
R01 · FY2013 · CA · contact PI
Molecular Aspects of Antitumor Antibodies$493,699
R01 · FY2012 · CA · contact PI
Study of FcR Genes: Macrophages and Lymphocytes$470,577
R01 · FY2012 · AI · contact PI
Optimizing vaccine efficacy through Fc receptors$422,628
P01 · FY2012 · AI · contact PI
FcR Deficient Mice Susceptibility to Pathogens$419,513
R01 · FY2012 · AI · contact PI
INNATE FUNCTIONS OF DENDRITIC CELLS IN AUTOREACTIVITY$1,901,862
P01 · FY2011 · AI · contact PI
Study of FcR Genes: Macrophages and Lymphocytes$473,310
R01 · FY2011 · AI · contact PI
FcR Deficient Mice Susceptibility to Pathogens$419,513
R01 · FY2011 · AI · contact PI
Optimizing vaccine efficacy through Fc receptors$374,185
P01 · FY2011 · AI · contact PI
Signaling in Dendritic Cell Function$369,741
P01 · FY2011 · AI · contact PI
Molecular Aspects of Antitumor Antibodies$324,199
R01 · FY2011 · CA · contact PI
Animal Services$214,475
P01 · FY2011 · AI · contact PI
Administrative Core$160,190
P01 · FY2011 · AI · contact PI
INNATE FUNCTIONS OF DENDRITIC CELLS IN AUTOREACTIVITY$1,868,726
P01 · FY2010 · AI · contact PI
Study of FcR Genes: Macrophages and Lymphocytes$480,683
R01 · FY2010 · AI · contact PI
FcR Deficient Mice Susceptibility to Pathogens$422,500
R01 · FY2010 · AI · contact PI
Optimizing vaccine efficacy through Fc receptors$371,742
P01 · FY2010 · AI · contact PI
Signaling in Dendritic Cell Function$363,886
P01 · FY2010 · AI · contact PI
Molecular Aspects of Antitumor Antibodies$334,226
R01 · FY2010 · CA · contact PI
Animal Services$210,544
P01 · FY2010 · AI · contact PI
Administrative Core$157,286
P01 · FY2010 · AI · contact PI
INNATE FUNCTIONS OF DENDRITIC CELLS IN AUTOREACTIVITY$2,001,275
P01 · FY2009 · AI · contact PI
Study of FcR Genes: Macrophages and Lymphocytes$473,960
R01 · FY2009 · AI · contact PI
FcR Deficient Mice Susceptibility to Pathogens$422,500
R01 · FY2009 · AI · contact PI
Signaling in Dendritic Cell Function$390,328
P01 · FY2009 · AI · contact PI
Optimizing vaccine efficacy through Fc receptors$368,872
P01 · FY2009 · AI · contact PI
Molecular Aspects of Antitumor Antibodies$333,402
R01 · FY2009 · CA · contact PI
Animal Services$225,270
P01 · FY2009 · AI · contact PI
Administrative Core$168,318
P01 · FY2009 · AI · contact PI
INNATE FUNCTIONS OF DENDRITIC CELLS IN AUTOREACTIVITY$1,775,873
P01 · FY2008 · AI · contact PI
Study of FcR Genes: Macrophages and Lymphocytes$457,914
R01 · FY2008 · AI · contact PI
FcR Deficient Mice Susceptibility to Pathogens$353,697
R01 · FY2008 · AI · contact PI
Signaling in Dendritic Cell Function$348,019
P01 · FY2008 · AI · contact PI
Molecular Aspects of Antitumor Antibodies$324,492
R01 · FY2008 · CA · contact PI
Animal Services$200,675
P01 · FY2008 · AI · contact PI
Administrative Core$147,498
P01 · FY2008 · AI · contact PI
DEVELOPMENT OF LYMPHOID ORGANS$1,102
P41 · FY2008 · RR · contact PI
INNATE FUNCTIONS OF DENDRITIC CELLS IN AUTOREACTIVITY$1,809,130
P01 · FY2007 · AI · contact PI
Study of Fc Receptor Genes: Macrophages and Lymphocytes$529,889
R37 · FY2007 · AI · contact PI
FcR Deficient Mice Susceptibility to Pathogens$360,546
R01 · FY2007 · AI · contact PI
Signaling in Dendritic Cell Function$341,497
P01 · FY2007 · AI · contact PI
Molecular Aspects of Antitumor Antibodies$324,491
R01 · FY2007 · CA · contact PI
Animal Services$194,940
P01 · FY2007 · AI · contact PI
Administrative$163,518
P01 · FY2007 · AI · contact PI
DEVELOPMENT OF LYMPHOID ORGANS$1,883
P41 · FY2007 · RR · contact PI
Innate Functions of Dendritic Cells in Autoreactivity$1,878,281
P01 · FY2006 · AI · contact PI
Study of Fc Receptor Genes: Macrophages and Lymphocytes$533,029
R37 · FY2006 · AI · contact PI
FcR Deficient Mice Susceptibility to Pathogens$371,315
R01 · FY2006 · AI · contact PI
Molecular Aspects of Antitumor Antibodies$334,182
R01 · FY2006 · CA · contact PI
DEVELOPMENT OF LYMPHOID ORGANS$1,233
P41 · FY2006 · RR · contact PI
Innate Functions of Dendritic Cells in Autoreactivity$1,873,281
P01 · FY2005 · AI
Study of Fc Receptor Genes: Macrophages and Lymphocytes$532,664
R37 · FY2005 · AI
Mechanism of antibody-mediated immunotherapy in AD$501,000
R01 · FY2005 · AG
Alternative Respiratory Chains of M. tuberculosis$379,782
R01 · FY2005 · AI
Molecular Aspects of Antitumor Antibodies$341,803
R01 · FY2005 · CA
DEVELOPMENT OF LYMPHOID ORGANS$1,190
P41 · FY2005 · RR
Innate Functions of Dendritic Cells in Autoreactivity$1,822,429
P01 · FY2004 · AI
Study of Fc Receptor Genes: Macrophages and Lymphocytes$517,151
R37 · FY2004 · AI
MODULATING AUTOIMMUNE DISEASE BY FC RECEPTORS$510,100
R01 · FY2004 · AI
Mechanism of antibody-mediated immunotherapy in AD$501,000
R01 · FY2004 · AG
FcR Deficient Mice Susceptibility to Pathogens$379,125
R01 · FY2004 · AI
Molecular Aspects of Antitumor Antibodies$341,213
R01 · FY2004 · CA
DEVELOPMENT OF LYMPHOID ORGANS$2,345
P41 · FY2004 · RR
Innate Functions of Dendritic Cells in Autoreactivity$1,772,553
P01 · FY2003 · AI
Study of Fc Receptor Genes: Macrophages and Lymphocytes$502,087
R37 · FY2003 · AI
Mechanism of antibody-mediated immunotherapy in AD$501,000
R01 · FY2003 · AG
MODULATING AUTOIMMUNE DISEASE BY FC RECEPTORS$499,793
R01 · FY2003 · AI
FCR DEFICIENT MICE SUSCEPTIBILITY TO PATHOGENS$296,248
R01 · FY2003 · AI
MOLECULAR ASPECTS OF ANTITUMOR ANTIBODIES$281,909
R01 · FY2003 · CA
Novel Strategies for Y pestis Immunotherapy$250,500
R21 · FY2003 · AI
Innate Functions of Dendritic Cells in Autoreactivity$1,550,959
P01 · FY2002 · AI
Mechanism of antibody-mediated immunotherapy in AD$501,000
R01 · FY2002 · AG
MODULATING AUTOIMMUNE DISEASE BY FC RECEPTORS$465,133
R01 · FY2002 · AI
STUDY OF FC RECEPTOR GENES;MACROPHAGES AND LYMPHOCYTES$385,232
R37 · FY2002 · AI
FCR DEFICIENT MICE SUSCEPTIBILITY TO PATHOGENS$288,259
R01 · FY2002 · AI
MOLECULAR ASPECTS OF ANTITUMOR ANTIBODIES$273,696
R01 · FY2002 · CA
Novel Strategies for Y pestis Immunotherapy$250,500
R21 · FY2002 · AI
Analysis of the Role of Antibodies in Sepsis$0
U54 · FY2002 · AI
Core--Genotyping facility$0
P01 · FY2002 · AI
ITAM/ITIM Signaling in Dendritic Cell Function$0
P01 · FY2002 · AI
Mechanism of antibody-mediated immunotherapy in AD$494,300
R01 · FY2001 · AG
MODULATING AUTOIMMUNE DISEASE BY FC RECEPTORS$454,681
R01 · FY2001 · AI
STUDY OF FC RECEPTOR GENES;MACROPHAGES AND LYMPHOCYTES$376,418
R37 · FY2001 · AI
FCR DEFICIENT MICE SUSCEPTIBILITY TO PATHOGENS$279,861
R01 · FY2001 · AI
MOLECULAR ASPECTS OF ANTITUMOR ANTIBODIES$265,725
R01 · FY2001 · CA
MODULATING AUTOIMMUNE DISEASE BY FC RECEPTORS$420,035
R01 · FY2000 · AI
STUDY OF FC RECEPTOR GENES;MACROPHAGES AND LYMPHOCYTES$367,861
R37 · FY2000 · AI
FCR DEFICIENT MICE SUSCEPTIBILITY TO PATHOGENS$271,711
R01 · FY2000 · AI
MOLECULAR ASPECTS OF ANTITUMOR ANTIBODIES$257,468
R01 · FY2000 · CA